The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double‐Blind, Placebo‐Controlled, Randomized Clinical Trial

OBJECTIVE: To prospectively assess the efficacy, general safety, and joint safety of fasinumab, an anti–nerve growth factor monoclonal antibody, in osteoarthritis (OA) hip and/or knee pain. METHODS: Patients with moderate‐to‐severe OA pain (knee or hip) and history of inadequate response or intolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Dakin, Paula, DiMartino, Stephen J., Gao, Haitao, Maloney, Jennifer, Kivitz, Alan J., Schnitzer, Thomas J., Stahl, Neil, Yancopoulos, George D., Geba, Gregory P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Osteoarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900077/
https://www.ncbi.nlm.nih.gov/pubmed/31207169
http://dx.doi.org/10.1002/art.41012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900077/
https://www.ncbi.nlm.nih.gov/pubmed/31207169
http://dx.doi.org/10.1002/art.41012

Ejemplares similares